863671-47-0

Upstream product

• 19158-51-1 P-toluenesulfonyl cyanide 
• 168049-26-1 tert-butyl (2S)-2-(azidomethyl)-1-pyrrolidinecarboxylate 

Downstream Products

• 863671-72-1 C₁₉H₂₈N₆O₂ 
• 863671-66-3 tert-butyl (2S)-2-{[5-(benzylamino)-1H-tetrazol-1-yl]methyl}-pyrrolidine-1-carboxylate 
• 863671-48-1 (S)-Boc-2-(5-phenylsulfanyltetrazol-1′-ylmethyl)pyrrolidine 
• 863671-60-7 C₁₈H₂₅N₅O₃ 
• 863671-54-9 C₁₇H₂₃N₅O₃ 
• 863671-49-2 (S)-2-(5-phenylsulfanyl-tetrazol-1-ylmethyl)-pyrrolidine 
• 1353642-13-3 tert-butyl (2S)-2-[(5-{[(1R)-1-phenylethyl]amino}-1H-tetrazol-1-yl)methyl]pyrrolidine-1-carboxylate 
• 1353642-14-4 tert-butyl (2S)-2-[(5-{[(1S)-1-phenylethyl]amino}-1H-tetrazol-1-yl)methyl]pyrrolidine-1-carboxylate 

Relevant academic research and scientific papers

MITOCHONDRIAL TARGETED STIMULATORS OF APOPTOSIS

Pro-apoptotic compounds having a tripartite structure: [in-line-formulae]A-L-B[/in-line-formulae] are disclosed. In these compounds A is an IBM mimetic moiety; L is a linker and B is a moiety that binds to a protein on the outer mitochondrial membrane. The compounds are useful for inducing cell apoptosis and therefore treating cancer. An example of such a compound is

1-alkyl-5-((di)alkylamino) tetrazoles: Building blocks for peptide surrogates

An approach to the synthesis of 1-alkyl-5-((di)alkylamino)tetrazoles by nucleophilic substitution in 1-alkyl-5-sulfonyltetrazoles with anions generated from the primary or secondary amines was developed. Tolerance of the method to the presence of some fun

Dimeric small molecule potentiators of apoptosis

Caspase activity and apoptosis are promoted using active, dimeric Smac peptide mimetics of the general formula M1-M2, wherein moieties M1 and M2 are monomeric Smac mimetics and L is a covalent linker. Target cancerous or inflammatory cells are contacted with an effective amount of an active, dimeric Smac mimetic, and a resultant increase in apoptosis of the target cells is detected. The contacting step may be effected by administering to a pharmaceutical composition comprising a therapeutically effective amount of the dimeric mimetic, wherein the individual may be subject to concurrent or antecedent radiation or chemotherapy for treatment of a neoproliferative pathology.